The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.
Patients over 18 years of age;
Histological diagnosis of clear cell renal cell carcinoma;
Evidence of advanced or metastatic disease;
Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI);
Previous neoplasms;
Previous antineoplastic treatments;
Previous steroid treatments;
Active viral infections (e.g., HCV, HIV, etc.);